This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Robinson, D. E. Articles by Macdonald, J. S. Search for Related Content PubMed PubMed Citation Articles by Robinson, D. E. Articles by Macdonald, J. S. Social Bookmarking                         What's this?

Background and Framework for ILSI's Collaborative Evaluation Program on Alternative Models for Carcinogenicity Assessment

International Life Sciences Institute, Health and Environmental Sciences Institute, 1 Thomas Circle, NW, Washington, DC 20005, drobinson{at}ilsi.org

James S. Macdonald

Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033

The willingness of the agencies involved in the regulation of pharmaceuticals to accept data from newly proposed models for carcinogenicity testing (eg, transgenic animals, neonatal rodent models, initiation-promotionmodels) has stimulated international interest in gaining experience and a greater understanding of the strengths and limitations of the specifi c models. Over a 4-year period, the International Life Sciences Institute (ILSI) Health and Environmental Science Institute (HESI) has coordinated a large-scale collaborative research program to help to better characterize the responsiveness of several models proposedfor use in carcinogenicity assessment. The overall objective of this partnership among industry, government, and academic scientists was to evaluate the ability of these new models to provide useful information for human cancer risk assessment. This research program reflected a commitment of nearly US$35 million by over 50 industrial, government, and academic laboratories from the United States, Europe, and Japan. Evaluation of the models required the development of standardized protocols to allow reproducibility and comparability of data obtained across multiple laboratories. Test compounds were selected on the basis of mechanistically meaningful carcinogenic activity or noncarcinogenicity in the rodent bioassay as well as humans. Criteria were established for dose selection, pathology review, quality control, and for evaluation of study outcome. The database from these studies represents an important contribution to the future application of new models for human cancer risk assessment. Beyond the data, the collaborative process by which the models were evaluated may also represent a prototype for assessing new methods in the future.

Key Words: Alternative carcinogen bioassay • carcinogenicity testing • carcinogens • cancer risk assessment • transgenic models • short-term cancer assays.

Toxicologic Pathology, Vol. 29, No. 1 suppl, 13-19 (2001)
DOI: 10.1080/019262301753178438


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. M. Cancel, T. Smith, U. Rehkemper, J. E. Dillberger, D. Sokal, and R. M. McClain A One-Year Neonatal Mouse Carcinogenesis Study of Quinacrine Dihydrochloride International Journal of Toxicology, March 1, 2006; 25(2): 109 - 118. [Abstract] [Full Text] [PDF]

				M. Okamura, M. Moto, M. Muguruma, T. Ito, M. Jin, Y. Kashida, and K. Mitsumori A 26-Week Carcinogenicity Study of 2-Amino-3-Methylimidazo[4,5-f]Quinoline in rasH2 Mice Toxicol Pathol, February 1, 2006; 34(2): 199 - 205. [Abstract] [Full Text] [PDF]

				M. J. Santostefano, D. J. Hoivik, and R. T. Miller Investigations of Clofibrate in Alternative Carcinogenicity Models International Journal of Toxicology, September 1, 2005; 24(5): 285 - 288. [Full Text] [PDF]

				C. E. Torrey, J. A. Campbell, D. J. Hoivik, R. T. Miller, J. S. Allen, P. C. Mann, K. Selinger, D. Rickert, P. M. Savina, and M. J. Santostefano Evaluation of the Carcinogenic Potential of Clofibrate in the p53+/- Mouse International Journal of Toxicology, September 1, 2005; 24(5): 289 - 299. [Abstract] [Full Text] [PDF]

				S. R. Nesfield, C. J. Clarke, D. J. Hoivik, R. T. Miller, J. S. Allen, K. Selinger, and M. J. Santostefano Evaluation of the Carcinogenic Potential of Clofibrate in the rasH2 Mouse International Journal of Toxicology, September 1, 2005; 24(5): 301 - 311. [Abstract] [Full Text] [PDF]

				C. E. Torrey, H. G. Wall, J. A. Campbell, P. Kwanyuen, D. J. Hoivik, R. T. Miller, J. S. Allen, M. J. Jayo, K. Selinger, P. M. Savina, et al. Evaluation of the Carcinogenic Potential of Clofibrate in FVB/Tg.AC Mouse After Oral Administration--Part I International Journal of Toxicology, September 1, 2005; 24(5): 313 - 325. [Abstract] [Full Text] [PDF]

				C. E. Torrey, H. G. Wall, J. A. Campbell, P. Kwanyuen, D. J. Hoivik, R. T. Miller, J. S. Allen, M. J. Jayo, K. Selinger, and M. J. Santostefano Evaluation of the Carcinogenic Potential of Clofibrate in the FVB/Tg.AC Mouse After Dermal Application--Part II International Journal of Toxicology, September 1, 2005; 24(5): 327 - 339. [Abstract] [Full Text] [PDF]

				S. R. Nesfield, T. C. Williams, D. J. Hoivik, R. T. Miller, J. S. Allen, K. Selinger, D. Rickert, and M. J. Santostefano Evaluation of the Carcinogenic Potential of Clofibrate in the Neonatal Mouse International Journal of Toxicology, September 1, 2005; 24(5): 341 - 348. [Abstract] [Full Text] [PDF]

				D. J. Hoivik, J. S. Allen, H. G. Wall, J. B. Nold, R. T. Miller, and M. J. Santostefano Studies Evaluating the Utility of N-Methyl-N-Nitrosourea as a Positive Control in Carcinogenicity Studies in the p53+/- Mouse International Journal of Toxicology, September 1, 2005; 24(5): 349 - 356. [Abstract] [Full Text] [PDF]

				B. A.R. Lina, R. A. Woutersen, J. P. Bruijntjes, J. Van Benthem, J. A.H. Van Den Berg, J. Monbaliu, B. J.J.M. Thoolen, R. B. Beems, and C. F. Van Kreijl Evaluation of the Xpa-Deficient Transgenic Mouse Model for Short-Term Carcinogenicity Testing: 9-Month Studies with Haloperidol, Reserpine, Phenacetin, and D-Mannitol Toxicol Pathol, February 1, 2004; 32(2): 192 - 201. [Abstract] [PDF]

				J. T. Macgregor Biomarkers of Cancer Risk and Therapeutic Benefit: New Technologies, New Opportunities, and Some Challenges Toxicol Pathol, January 1, 2004; 32(1_suppl): 99 - 105. [Abstract] [PDF]

				K. L. Thompson and F. D. Sistare Selection of Drugs to Test the Specificity of the Tg.AC Assay by Screening for Induction of the gadd153 Promoter in Vitro Toxicol. Sci., August 1, 2003; 74(2): 260 - 270. [Abstract] [Full Text] [PDF]

				S. R. Payne and C. J. Kemp p27 Kip1 (Cdkn1b)-Deficient Mice Are Susceptible to Chemical Carcinogenesis and May Be a Useful Model for Carcinogen Screening Toxicol Pathol, June 1, 2003; 31(4): 355 - 363. [Abstract] [PDF]

				M. Takaoka, S. Sehata, T. Maejima, T. Imai, M. Tor, H. Satoh, K. Toyosawa, Z.-Y. Tanakamaru, T. Adachi, S. Hisada, et al. Interlaboratory Comparison of Short-Term Carcinogenicity Studies Using CB6F1-rasH2 Transgenic Mice Toxicol Pathol, February 1, 2003; 31(2): 191 - 199. [Abstract] [PDF]

				Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment Statement on ILSI/HESI Research Programme on Alternative Cancer Models Toxicol Pathol, February 1, 2003; 31(2): 254 - 257. [PDF]

				J. M. Petruska, D. W. Frank, G. B. Freeman, E. W. Evans, and J. S. Macdonald Toxicity and Carcinogenicity Studies of Chlorpromazine Hydrochloride and p-Cresidine in the p53 Heterozygous Mouse Model Toxicol Pathol, October 1, 2002; 30(6): 696 - 704. [Abstract] [PDF]